Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJX-653 in Postmenopausal Women With Moderate to Severe VMS
NCT04278872Phase 2Terminated
- Sponsor
- Sojournix
- Start
- Nov 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in vasomotor symptoms comparing SJX-653 with Placebo (2 arms). Primary endpoint: Mean Change in Average Daily Frequency of Moderate to Severe Vasomotor Symptoms (VMS) From Baseline at 4 weeks. Started Nov 2020; status: terminated.
02
Drugs
SJX-653
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT04278872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278872.